Ependymoma - Pipeline Review, H1 2012

Global Markets Direct, June 2012, Pages: 52

Ependymoma – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Ependymoma - Pipeline Review, H1 2012', provides an overview of the Ependymoma therapeutic pipeline. This report provides information on the therapeutic development for Ependymoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ependymoma. 'Ependymoma - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Ependymoma.
- A review of the Ependymoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Ependymoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Ependymoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Ependymoma pipeline depth and focus of Ependymoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Ependymoma Therapeutic Products under Development, Key Players in Ependymoma Therapeutics, Ependymoma Pipeline Overview, Ependymoma Pipeline, Ependymoma Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ependymoma Overview
Therapeutics Development
An Overview of Pipeline Products for Ependymoma
Ependymoma Therapeutics under Development by Companies
Ependymoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Ependymoma Therapeutics – Products under Development by Companies
Ependymoma Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Ependymoma Therapeutics Development
OSI Pharmaceuticals, Inc.
Ependymoma – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Temozolomide + Lapatinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide + Etoposide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GW572016 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Camptosar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avastin + Tykerb - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Torisel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide + Lapatinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Etoposide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Etoposide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Verteporfin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vincristine + Carboplatin + Cyclophosphamide + Etoposide + G-CSF + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dendritic cells + Imiquimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tarceva - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide + Etoposide + Trofosfamid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sirolimus + Celecoxib + Etoposide + Cyclophosphamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Cyclophosphamide + Etoposide + Vincristine + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ependymoma Therapeutics – Drug Profile Updates
Ependymoma Therapeutics - Dormant Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Ependymoma, H1 2012
Products under Development for Ependymoma – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
OSI Pharmaceuticals, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Ependymoma Therapeutics – Drug Profile Updates
Ependymoma Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Ependymoma, H1 2012
Products under Development for Ependymoma – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Candidiasis - Pipeline Review, H1 2013
• Burns - Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2012
• Scar - Pipeline Review, H1 2013
• Sarcopenia - Pipeline Review, H1 2013
• Rhinitis - Pipeline Review, H1 2013
• Herpes Simplex Infections - Pipeline Review, H1 2013
• Pandemic Influenza – Pipeline Review, H1 2013